AU2017234679A1 - Engineered trail for cancer therapy - Google Patents

Engineered trail for cancer therapy Download PDF

Info

Publication number
AU2017234679A1
AU2017234679A1 AU2017234679A AU2017234679A AU2017234679A1 AU 2017234679 A1 AU2017234679 A1 AU 2017234679A1 AU 2017234679 A AU2017234679 A AU 2017234679A AU 2017234679 A AU2017234679 A AU 2017234679A AU 2017234679 A1 AU2017234679 A1 AU 2017234679A1
Authority
AU
Australia
Prior art keywords
ser
gly
leu
lys
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017234679A
Other languages
English (en)
Inventor
Diana Hung-yi Chai MARCANTONIO
Stephen L. SAZINSKY
Birgit M. Schoeberl
Eric M. Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of AU2017234679A1 publication Critical patent/AU2017234679A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017234679A 2016-03-16 2017-03-16 Engineered trail for cancer therapy Abandoned AU2017234679A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662309352P 2016-03-16 2016-03-16
US62/309,352 2016-03-16
US201662323501P 2016-04-15 2016-04-15
US62/323,501 2016-04-15
US201762445556P 2017-01-12 2017-01-12
US62/445,556 2017-01-12
PCT/US2017/022789 WO2017161173A1 (en) 2016-03-16 2017-03-16 Engineered trail for cancer therapy

Publications (1)

Publication Number Publication Date
AU2017234679A1 true AU2017234679A1 (en) 2018-08-30

Family

ID=58413224

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017234679A Abandoned AU2017234679A1 (en) 2016-03-16 2017-03-16 Engineered trail for cancer therapy

Country Status (10)

Country Link
US (1) US20190077870A1 (https=)
EP (1) EP3430034A1 (https=)
JP (1) JP2019518713A (https=)
KR (1) KR20180127407A (https=)
CN (1) CN108884142A (https=)
AU (1) AU2017234679A1 (https=)
CA (1) CA3017622A1 (https=)
IL (1) IL261267A (https=)
MX (1) MX2018011219A (https=)
WO (1) WO2017161173A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3348578B1 (en) * 2015-10-22 2019-10-09 Chengdu Huachuang Biotechnology Co., Ltd Double-target mutein mur6s4tr of trail, and preparation method and use thereof
JP2019517570A (ja) * 2016-06-13 2019-06-24 メリマック ファーマシューティカルズ インコーポレーティッド Ｔｒａｉｌベースの治療剤または細胞死受容体アゴニストを用いて患者を選択および治療する方法
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂
WO2022080865A2 (ko) * 2020-10-13 2022-04-21 신동준 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH0822239B2 (ja) * 1988-07-07 1996-03-06 株式会社蛋白工学研究所 変異ヒト腫傷壊死因子
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CN101633692A (zh) * 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
SI1706424T1 (sl) 2004-01-12 2010-01-29 Applied Molecular Evolution Variante fc regij
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
ES2538122T3 (es) * 2008-07-21 2015-06-17 Apogenix Gmbh Moléculas de una sola cadena de TNFSF
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP2437767B1 (en) * 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
WO2011139681A1 (en) 2010-04-26 2011-11-10 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
EP2468764A1 (en) * 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants
JP6047142B2 (ja) * 2011-04-01 2016-12-21 ウニヴェルズィテート シュトゥットガルト 抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
CN111592601A (zh) * 2011-07-06 2020-08-28 江苏靶标生物医药研究所有限公司 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用
NO2776305T3 (https=) * 2014-04-23 2018-01-27
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof

Also Published As

Publication number Publication date
MX2018011219A (es) 2019-01-10
CN108884142A (zh) 2018-11-23
CA3017622A1 (en) 2017-09-21
IL261267A (en) 2018-10-31
WO2017161173A1 (en) 2017-09-21
JP2019518713A (ja) 2019-07-04
US20190077870A1 (en) 2019-03-14
KR20180127407A (ko) 2018-11-28
EP3430034A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
JP7587656B2 (ja) Ｐｄ－ｌ１及びｃｄ１３７に結合する抗体分子
KR102427192B1 (ko) 항-인간 4-1bb 항체 및 그의 용도
US20210122805A1 (en) Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
KR102426765B1 (ko) Cd137에 대한 신규한 이중특이성 폴리펩타이드
TW202227494A (zh) 多特異性免疫靶向分子及其用途
KR20210091710A (ko) PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도
KR20220016945A (ko) 다중특이적 단백질
KR20180031728A (ko) 다가 및 다중특이적 gitr 결합 융합 단백질
KR20230029622A (ko) April 및 baff 억제 면역조절 단백질 및 사용 방법
JP2016510755A (ja) 抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
JP2023530760A (ja) Ｈｅｒ２を標的とするアゴニストＣＤ２８抗原結合分子
AU2017234679A1 (en) Engineered trail for cancer therapy
CN111465618A (zh) 双特异性cd16-结合分子及其在疾病治疗中的用途
CN117120478A (zh) 一种抗原结合分子
CN111164101B (zh) 甲状腺素视黄质运载蛋白免疫球蛋白融合体
KR102956517B1 (ko) 트랜스타이레틴 면역글로불린 융합
HK40130060A (zh) 利用靶向FAP的淋巴毒素β受体激动剂的组合疗法
CN121358775A (zh) 利用靶向FAP的淋巴毒素β受体激动剂的组合疗法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application